Hoppa till innehållet

OMXSPI+0,50%

S&P 500+0,80%

FTSE 100+0,54%

DAX+0,01%

NIKKEI+1,14%
BioStock: Saniona carves path to disrupt the epilepsy market

Saniona's expertise in ion channel modulation has resulted in a vast pipeline of drug candidates targeting a number of central nervous system disorders. However, the company's main focus is epilepsy, where the medical need and market potential are quite significant. The lead candidate in the epilepsy programme, SAN711, is poised for proof-of-concept studies. To secure its development, and to bring forward other epilepsy candidates towards the clinic, Saniona is carrying out a SEK 140 million rights issue.

Read the article at biostock.se:

Saniona carves path to disrupt the epilepsy market - BioStock (https://www.biostock.se/en/2024/01/saniona-banar-vag-for-nydanande-epilepsimarknad/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Source:Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera